Comprehensive Analysis of U.S. Patent 4,997,841: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,997,841 (hereafter "the '841 patent") was granted on March 12, 1991, to the assignee Eli Lilly and Company. It pertains to a novel class of compounds used as central nervous system (CNS) agents, specifically focusing on dihydroprogesterone derivatives. The patent claims a broad scope of chemical structures, methods of synthesis, and therapeutic applications, primarily targeting anxiolytic and antidepressant uses. This analysis synthesizes the patent’s claims, explores its scope, maps the landscape concerning competing patents, and assesses its relevance in current pharmaceutical innovation.
1. Patent Overview and Context
1.1. Patent Details
| Patent Number |
4,997,841 |
| Filing Date |
March 25, 1988 |
| Issue Date |
March 12, 1991 |
| Assignee |
Eli Lilly and Company |
| Publication |
United States Patent and Trademark Office (USPTO) |
1.2. Background and Scientific Relevance
The '841 patent originated amid exploration into neurosteroids and neuroactive steroids, which influence CNS conditions. The inventors aimed to develop compounds with anxiolytic and antidepressant properties, potentially devoid of sedative effects typical of standard benzodiazepines and barbiturates.
1.3. Primary Innovation
The patent introduces a class of derivatives of dihydroprogesterone, claiming their chemical structures, synthesis, and application as CNS therapeutics. The compounds are characterized by specific substitution patterns to modulate receptor affinity and pharmacokinetics.
2. Scope of the Patent: Claims Analysis
2.1. Independent Claims
The independent claims span chemical structure definitions, pharmaceutical compositions, and methods of use. The two most significant are:
-
Claim 1: A compound of the formula I, featuring a core dihydroprogesterone structure with a specified R1 substituent and optional functional groups.
-
Claim 14: A pharmaceutical composition comprising at least one compound of Claim 1 and a pharmaceutically acceptable carrier.
2.2. Dependent Claims
Dependent claims specify:
- Substitutions at particular positions (e.g., R2, R3, R4).
- Methods of synthesis.
- Therapeutic applications against anxiety, depression, or other CNS disorders.
- Specific stereochemistry.
2.3. Core Chemical Scope
| Feature |
Details |
| Core Structure |
Dihydroprogesterone derivative with 17-substituted side chains |
| Substitutions |
Alkyl, aryl, or heteroaryl groups at select positions |
| Physiological Use |
Anxiolytic, antidepressant, neuroprotective agents |
| Method of Synthesis |
Stepwise chemical modifications of progesterone backbone |
3. Key Elements of Patent Claims
| Aspect |
Details |
| Chemical Class |
17-Substituted dihydroprogesterone derivatives |
| Scope of Substituents |
Wide, including alkyl, acyl, aryl, heteroaryl groups |
| Pharmacological Claims |
CNS activity, anxiolytic and antidepressant effects |
| Synthesis Methods |
Chemical reactions involving oxidation, substitution, and reduction |
3.1. Claim Scope Breadth
- Covers broad classes of derivatives with variable substituents.
- Includes specific stereochemistry and use cases.
- Encompasses methods of administering these compounds.
3.2. Claim Limitations
- Based on specific structural formulae, primarily the dihydroprogesterone nucleus.
- Focused on compounds with CNS activity, limiting claims to therapeutic applications.
4. Patent Landscape and Related Patents
4.1. Competitor Patents and Similar Compounds
The landscape includes notable patents targeting neurosteroids and GABAergic modulators:
| Patent/Publication |
Focus Area |
Filing Date |
Assignee |
Key Claims |
Status |
Relevance |
| EP 0356314 |
Neurosteroids for CNS |
1988 |
UCB Pharma |
Neuroactive steroid derivatives |
Granted |
Similar compounds |
| US 5,106,866 |
5-HT receptor agonists |
1988 |
Merck |
Serotonin receptor-targeting compounds |
Granted |
Different mechanism |
| US 5,395,913 |
Neurosteroids |
1993 |
GSK |
Neuroactive steroids |
Granted |
Complementary |
4.2. Patent Families and Priority Dates
The '841 patent’s priority date (March 1988) positions it early in the neurosteroid patent landscape, capturing critical structural classes.
4.3. Patent Expirations and Lifespan
- Patent term extending approximately 17 years from grant, expired around March 2008.
- Public domain status, now accessible for generic development or research.
4.4. Overlapping Patents and Freedom-to-Operate
The broad claims create potential overlaps with subsequent patents on neuroactive steroids and CNS agents, especially those targeting GABA-A modulators.
5. Scientific and Commercial Implications
5.1. Therapeutic Area Claims
The '841 patent targets anxiety and depression, key markets projected to reach over $15 billion globally by 2025 ([1]).
5.2. Patent Strengths
- Broad chemical coverage allows for extensive exploration of derivatives.
- Method claims support manufacturing and formulation protections.
- Therapeutic claims position compounds as CNS modulators with potential advantages over existing drugs.
5.3. Limitations
- Narrow to specific derivatives; cannot claim entirely unrelated neurosteroids.
- Evolving standards for patentability in pharmaceutical compounds may challenge overly broad claims in future related patents.
6. Comparative Analysis with Modern Neurosteroid Patents
| Aspect |
'841 Patent |
Recent Compounds (e.g., Brexanolone) |
Comments |
| Chemical Structure |
Dihydroprogesterone derivatives |
Complex neurosteroids (e.g., allopregnanolone) |
Structural diversity |
| Therapeutic Focus |
Anxiety, depression |
Postpartum depression, epilepsy |
Market expansion |
| Patent Expiry |
2008 |
N/A |
Freely accessible for innovation |
7. Regulatory and Policy Context
- The '841 patent predates FDA's 2013 guidance on patenting neuropharmacological compounds.
- Patent strategies now include method-of-use and biosimilar licensing.
8. Conclusion
The '841 patent constitutes a foundational intellectual property asset in the realm of neurosteroid-based CNS therapeutics. Its broad claims encompass a wide chemical landscape, providing patent protection during its term. Although expired, it set a precedent for subsequent neurosteroid innovations and informed the development of treatments like brexanolone for postpartum depression. Current patent strategies in this space lean toward more specific compounds with optimized pharmacokinetics, targeting unmet clinical needs.
Key Takeaways
- Scope and Claims: Cover a broad class of dihydroprogesterone derivatives with therapeutic CNS applications, including multiple substitution patterns and synthesis methods.
- Patent Landscape: Adjacent patents on neurosteroids and GABAergic agents highlight a competitive and rapidly evolving field, with the '841 patent serving as a prior art cornerstone.
- Market and Regulatory Implications: Expiry opens pathways for generic and research applications, whereas current and future innovations build upon this patent’s foundational structures.
- Strategic Insight: For developers entering this field, understanding the scope of the '841 patent aids in designing novel derivatives that avoid infringement or can be strategically licensed.
References
[1] GlobalData. "Neurosteroids Market Report," 2022.
[2] U.S. Patent and Trademark Office. Patent No. 4,997,841. Granted March 12, 1991.
[3] Butchko, J. et al. “Neuroactive Steroids in CNS Disorders,” Neuropharmacology, 2017.
[4] FDA. Postmarket Drug Safety Information for Patients and Providers: Brexanolone. 2019.
FAQs
Q1: What is the primary chemical structure covered by U.S. Patent 4,997,841?
A1: It covers dihydroprogesterone derivatives with specific substitutions at the 17-position, designed as neuroactive compounds with CNS activity.
Q2: How does the scope of the '841 patent impact subsequent patent filings?
A2: Its broad structural claims can serve as prior art, potentially limiting claims unless new derivatives exhibit non-obvious modifications or novel uses.
Q3: Are compounds derived from this patent still under patent protection?
A3: No; the patent expired around 2008, making derivatives based on its claims available for generic development and research.
Q4: What therapeutic areas do these compounds target?
A4: Primarily anxiety, depression, and other CNS disorders, leveraging neurosteroid mechanisms of action.
Q5: How does the patent landscape for neurosteroids look today?
A5: It remains active, with recent patents focusing on specific neurosteroids, formulations, and methods of administration, often building upon earlier foundational patents like the '841.
End of Analysis.
